Research progress of azvudine in the treatment of novel coronavirus infection  

作　　者：Dongmei Zhang Suling Chen Chao Liu 

机构地区：[1]The First Clinical College of Changzhi Medical College,Teaching and Research Office of Infectious Diseases of First Clinical College Attached to Changzhi Medical College [2]Department of Infectious Disease,Heping Hospital Affiliated to Changzhi Medical College,Changzhi,046000,ShanXi Province,China

出　　处：《感染控制(英文)》2024年第1期32-40,共9页

基　　金：supported by Science and Technology Innovation Project of Shanxi Provincial Colleges and Universities(2021L352);2021 Doctoral Research Startup Fund(BS202105)of Changzhi Medical College;2022 Teaching Reform and Innovation Project of Changzhi Medical College(J2022005).

摘　　要：The novel coronavirus known as severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)is constantly mutating,with Omicron and its branches being the main circulating strains in the ongoing global pandemic.Azvudine,a small-molecule drug independently developed in China to treat HIV,is the first nucleoside-based,dual-targeted antiviral agent.Clinical studies have shown that azvudine has relatively good safety and efficacy profiles.This article provides an overview of the background,mechanism of action,efficacy,safety,and drug interactions of azvudine for the treatment of SARS-CoV-2 infection.

关 键 词：COVID-19 SARS CoV-2 azvudine SAFETY EFFICACY 

分 类 号：R37[医药卫生—病原生物学]